605.00
-5.00
(-0.82%)
As of 8:31:45 AM GMT+1. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in EUR | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 19 | 10 | 26 | 28 |
| Avg. Estimate | 677.26M | 707.56M | 2.08B | 3.12B |
| Low Estimate | 538.06M | 650.48M | 1.96B | 2.21B |
| High Estimate | 737.2M | 777.36M | 2.19B | 3.73B |
| Year Ago Sales | 385.67M | 383.84M | 1.17B | 2.08B |
| Sales Growth (year/est) | 75.61% | 84.34% | 77.51% | 49.96% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 1AEA.F | -- | -- | -- | -- |
| S&P 500 | 9.90% | 11.00% | 14.01% | 13.54% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/14/2025 |
| Reiterates | Truist Securities: Buy to Buy | 1/14/2025 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 1/14/2025 |
| Maintains | Piper Sandler: Overweight to Overweight | 1/7/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 12/19/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 11/21/2024 |